JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 154.37 Billion KRW | -12.11% |
| 2022 | 175.64 Billion KRW | -17.06% |
| 2021 | 211.77 Billion KRW | 23.29% |
| 2020 | 171.76 Billion KRW | 17.92% |
| 2019 | 145.66 Billion KRW | 0.96% |
| 2018 | 144.27 Billion KRW | -8.84% |
| 2017 | 158.26 Billion KRW | -8.6% |
| 2016 | 173.15 Billion KRW | -38.67% |
| 2015 | 282.32 Billion KRW | 3.59% |
| 2014 | 272.53 Billion KRW | -12.9% |
| 2013 | 312.91 Billion KRW | -12.05% |
| 2012 | 355.8 Billion KRW | -14.24% |
| 2011 | 414.89 Billion KRW | 62.02% |
| 2010 | 256.07 Billion KRW | 21.94% |
| 2009 | 210.01 Billion KRW | 55.34% |
| 2008 | 135.19 Billion KRW | 50.17% |
| 2007 | 90.02 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 118.26 Billion KRW | -23.39% |
| 2024 Q2 | 116.53 Billion KRW | -1.46% |
| 2023 Q1 | 257.86 Billion KRW | 46.81% |
| 2023 Q2 | 208.39 Billion KRW | -19.19% |
| 2023 FY | 154.37 Billion KRW | -12.11% |
| 2023 Q3 | 178.58 Billion KRW | -14.3% |
| 2023 Q4 | 154.37 Billion KRW | -13.56% |
| 2022 Q4 | 175.64 Billion KRW | -10.35% |
| 2022 Q2 | 209.1 Billion KRW | -4.36% |
| 2022 Q3 | 195.91 Billion KRW | -6.31% |
| 2022 Q1 | 218.63 Billion KRW | 3.24% |
| 2022 FY | 175.64 Billion KRW | -17.06% |
| 2021 Q3 | 186.52 Billion KRW | -10.78% |
| 2021 FY | 211.77 Billion KRW | 23.29% |
| 2021 Q1 | 149.37 Billion KRW | -13.04% |
| 2021 Q4 | 211.77 Billion KRW | 13.54% |
| 2021 Q2 | 209.05 Billion KRW | 39.96% |
| 2020 Q2 | 166.89 Billion KRW | 13.91% |
| 2020 Q1 | 146.51 Billion KRW | 0.59% |
| 2020 Q3 | 142.54 Billion KRW | -14.59% |
| 2020 Q4 | 171.76 Billion KRW | 20.5% |
| 2020 FY | 171.76 Billion KRW | 17.92% |
| 2019 Q2 | 170.48 Billion KRW | -1.61% |
| 2019 Q1 | 173.27 Billion KRW | 20.1% |
| 2019 FY | 145.66 Billion KRW | 0.96% |
| 2019 Q3 | 161.47 Billion KRW | -5.28% |
| 2019 Q4 | 145.66 Billion KRW | -9.79% |
| 2018 Q3 | 116.58 Billion KRW | -23.08% |
| 2018 Q2 | 151.57 Billion KRW | -14.87% |
| 2018 Q1 | 178.03 Billion KRW | 12.5% |
| 2018 FY | 144.27 Billion KRW | -8.84% |
| 2018 Q4 | 144.27 Billion KRW | 23.75% |
| 2017 Q3 | 156.39 Billion KRW | -9.24% |
| 2017 Q2 | 172.3 Billion KRW | 2.24% |
| 2017 Q1 | 168.53 Billion KRW | -2.67% |
| 2017 Q4 | 158.26 Billion KRW | 1.19% |
| 2017 FY | 158.26 Billion KRW | -8.6% |
| 2016 FY | 173.15 Billion KRW | -38.67% |
| 2016 Q1 | 284.54 Billion KRW | 0.78% |
| 2016 Q2 | 271.13 Billion KRW | -4.71% |
| 2016 Q3 | 243.93 Billion KRW | -10.03% |
| 2016 Q4 | 173.15 Billion KRW | -29.02% |
| 2015 Q2 | 281.13 Billion KRW | -6.17% |
| 2015 Q1 | 299.6 Billion KRW | 9.93% |
| 2015 Q4 | 282.32 Billion KRW | -3.59% |
| 2015 Q3 | 292.84 Billion KRW | 4.17% |
| 2015 FY | 282.32 Billion KRW | 3.59% |
| 2014 Q2 | 315.03 Billion KRW | 1.61% |
| 2014 Q1 | 310.05 Billion KRW | -0.91% |
| 2014 Q3 | 307.14 Billion KRW | -2.5% |
| 2014 Q4 | 272.53 Billion KRW | -11.27% |
| 2014 FY | 272.53 Billion KRW | -12.9% |
| 2013 FY | 312.91 Billion KRW | -12.05% |
| 2013 Q4 | 312.91 Billion KRW | -6.51% |
| 2013 Q3 | 334.71 Billion KRW | 1.15% |
| 2013 Q2 | 330.89 Billion KRW | -8.39% |
| 2013 Q1 | 361.22 Billion KRW | 1.52% |
| 2012 Q1 | 414.17 Billion KRW | 0.0% |
| 2012 FY | 355.8 Billion KRW | -14.24% |
| 2012 Q4 | 355.8 Billion KRW | 0.0% |
| 2011 FY | 414.89 Billion KRW | 62.02% |
| 2011 Q3 | 402.86 Billion KRW | 5.63% |
| 2011 Q1 | 382.81 Billion KRW | 49.49% |
| 2011 Q2 | 381.38 Billion KRW | -0.37% |
| 2010 Q1 | 255.47 Billion KRW | 21.65% |
| 2010 Q2 | 261.18 Billion KRW | 2.23% |
| 2010 FY | 256.07 Billion KRW | 21.94% |
| 2010 Q4 | 256.07 Billion KRW | -5.97% |
| 2010 Q3 | 272.33 Billion KRW | 4.27% |
| 2009 Q1 | 183.61 Billion KRW | 35.82% |
| 2009 Q4 | 210.01 Billion KRW | 4.11% |
| 2009 Q3 | 201.72 Billion KRW | -0.28% |
| 2009 FY | 210.01 Billion KRW | 55.34% |
| 2009 Q2 | 202.28 Billion KRW | 10.17% |
| 2008 FY | 135.19 Billion KRW | 50.17% |
| 2008 Q4 | 135.19 Billion KRW | 0.15% |
| 2008 Q3 | 134.99 Billion KRW | 14.07% |
| 2008 Q2 | 118.34 Billion KRW | 10.97% |
| 2008 Q1 | 106.64 Billion KRW | 18.46% |
| 2007 Q4 | 90.02 Billion KRW | 5.65% |
| 2007 FY | 90.02 Billion KRW | 0.0% |
| 2007 Q2 | 99.65 Billion KRW | -6.3% |
| 2007 Q1 | 106.35 Billion KRW | 0.0% |
| 2007 Q3 | 85.21 Billion KRW | -14.49% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1653.77% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 73.013% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 50.343% |
| HANDOK Inc. | 283.45 Billion KRW | 45.539% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -669.081% |
| Yuhan Corporation | -69.18 Billion KRW | 323.124% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 20.407% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 4288.253% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 70.192% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 575.986% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -103.993% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -319.062% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -87.071% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -514.819% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1653.77% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 196.574% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 23.178% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 9.695% |
| JW Holdings Corporation | 480.68 Billion KRW | 67.885% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 6.204% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -131244.644% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -6465.305% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -571.137% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 11.774% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -197.013% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1653.77% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 2.48% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 56.901% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 0.0% |
| Yuhan Corporation | -69.18 Billion KRW | 323.124% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | -13.515% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -158.69% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 64.028% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | -32.808% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -839.849% |
| CKD Bio Corp. | 143.29 Billion KRW | -7.729% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -33.002% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 741.564% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 445.086% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -6465.305% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 63.492% |
| Boryung Corporation | 187.72 Billion KRW | 17.769% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 314.882% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -103.993% |
| JW Lifescience Corporation | 26.09 Billion KRW | -491.672% |